SCHEMBL5756015

SCHEMBL5756015

CCOC(=O)c1cccc2[nH]c(-c3cc[nH]n3)cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.49
MAPT P10636 6/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HCRTR1 O43613 1/20 0.43
RAB9A P51151 1/20 0.43
TSHR P16473 1/20 0.43
NPC1 O15118 2/20 0.43
GABRP O00591 1/20 0.43
GABRD O14764 1/20 0.43
PDE5A O76074 1/20 0.43
LMNA P02545 1/20 0.43
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5755265 0.82 PBRM1 (0.40) KDM4EALDH1A1MEN1KMT2ARAB9A
SCHEMBL5752743 0.81 PARP1 (0.40) KDM4EALDH1A1
SCHEMBL5757017 0.81 HDAC11 (0.43) KDM4EMAPTALDH1A1RAB9ATSHR
SCHEMBL5756543 0.81 HDAC11 (0.39) KDM4EMAPTSMN1; SMN2ALDH1A1TSHR
SCHEMBL5752805 0.79 TSHR (0.47) KDM4EMAPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL5752672 0.79 HDAC11 (0.41) KDM4EMAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL9132050 0.78 KDM4E (0.59) KDM4EMAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL5757543 0.77 KDM4E (0.46) KDM4EMAPTSMN1; SMN2ALDH1A1LMNA
SCHEMBL5756899 0.77 KMT2A (0.41) KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL6488203 0.76 DAO (0.46) KDM4EMAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648884-A2 PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2006-04-26 EP disclosed
US-20050032869-A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2005-02-10 US disclosed
WO-2005005414-A2 PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032869-A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K9, MAP3K20, MAP3K19 KDM4E 765/4885MAPT 1668/4885SMN1; SMN2 4414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.